HIV prevention clinical trials' community engagement guidelines: inequality, and ethical conflicts.
Loading...
Date
2020-06-05T00:00:00Z
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Routledge Taylor and Francis group
Abstract
In 2004 and 2005, the first clinical trials were launched to investigate the use of tenofovir for HIV prevention in Cambodia,Cameroon, Nigeria and Thailand. Controversies erupted over the ethical integrity of the research protocol. We reflect on the events that ledto the controversies and identified that scientific and ethical concerns raised by members of local communities at each of these sites wereerased by trialists, causing crisis that led to premature shut down the early PrEP trials. In the aftermath of these trials, the World HealthOrganisation, UNAIDS, and AVAC developed ethics guidelines intended to recognize the concerns as authentic, and developed guidelines toimprove researchers' engagement of communities in biomedical HIV prevention trial design and implementation. Our findings suggest thatthe ethics guidelines are limited in its ability to address power inequalities that leads to voice erasures and non-recognition of localcompetencies. Rather the ethical documents enabled trialists to gain a new sense of authority through the interpretations of ethical researchconduct enabling trialists regain power that can further entrench inequality and voice erasures. To address concerns with what seems anintractable problem, we suggested models of engagement for off-shored research may be the option.
Description
20p
Keywords
Cambodia, Cameroon, HIV, HIV prevention, Malawi, Nigeria, PrEP, clinical trials, community engagement, ethics
Citation
Folayan, M. O., & Peterson, K. (2020). HIV prevention clinical trials’ community engagement guidelines: inequality, and ethical conflicts. Global Bioethics, 31(1), 47-66.